inVentiv Health Commercial

inventivhealth.com

INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, our global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information on our Raleigh, N.C.-based company, visit incresearch.com or inventivhealth.com.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIG PHARMA RETURNING TO U.S. PRICE HIKES IN JANUARY AFTER PAUSE

Reuters: | February 19, 2020

news image

Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...

Read More

Business Insights

AQEMIA ANNOUNCES AN EXTENSION OF ITS FIRST COLLABORATION WITH SANOFI ABOUT AI AND QUANTUM PHYSICS-DRIVEN DRUG DISCOVERY IN ONCOLOGY

Aqemia | June 16, 2022

news image

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi. This new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi. This initial collaboration resulted...

Read More

Pharma Tech

IACTA PHARMACEUTICALS AND TALLC CORPORATION ANNOUNCE STRATEGIC COLLABORATION TO UTILIZE NOVEL SMARTCELLE TOPICAL DELIVERY TECHNOLOGY

IACTA Pharmaceuticals, Inc. | December 16, 2021

news image

IACTA Pharmaceuticals, Inc. an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, announced that they are entering into a strategic collaboration and licensing agreement. The agreement grants IACTA the use of TALLC’s proprietary SmartCelle™ micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development. IACTA...

Read More

Business Insights

AKORN ANNOUNCES FDA-APPROVED GENERIC CETRORELIX ACETATE FOR INJECTION 0.25 MG

Akorn Pharmaceuticals | August 17, 2022

news image

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg. This is the first approved AP-Rated bioequivalent version of Merck Serono's Cetrotide®.1 "We are pleased to announce the first approved AP-rated generic option for women receiving fertility treatments. As an increasing number of infants are being conceived via the use of ART, ...

Read More
news image

BIG PHARMA RETURNING TO U.S. PRICE HIKES IN JANUARY AFTER PAUSE

Reuters: | February 19, 2020

Novartis AG (NOVN.S) and Bayer AG (BAYGn.DE) are among nearly 30 drugmakers that have taken steps to raise the U.S. prices of their medicines in January, ending a self-declared halt to increases made by a pharma industry under pressure from the Trump administration, according to documents seen by Reuters. Other drugmakers set to raise prices at the start of 2019 include Allergan Plc (AGN.N), GlaxoSmithKline Plc (GSK.L), Amgen Inc (AMGN.O), AstraZeneca Plc (AZN.L) and Biogen Inc (BIIB.O), the doc...

Read More
news image

Business Insights

AQEMIA ANNOUNCES AN EXTENSION OF ITS FIRST COLLABORATION WITH SANOFI ABOUT AI AND QUANTUM PHYSICS-DRIVEN DRUG DISCOVERY IN ONCOLOGY

Aqemia | June 16, 2022

Aqemia, the next-gen pharmatech company leveraging artificial intelligence and quantum physics announced, today that it has entered a new research collaboration with Sanofi. This new agreement is a follow-up to a Research Collaboration initiated at the end 2020 by Sanofi to bring the unique technologies of Aqemia to the design and discovery of novel molecules in several projects in oncology, a priority therapeutic area for Sanofi. This initial collaboration resulted...

Read More
news image

Pharma Tech

IACTA PHARMACEUTICALS AND TALLC CORPORATION ANNOUNCE STRATEGIC COLLABORATION TO UTILIZE NOVEL SMARTCELLE TOPICAL DELIVERY TECHNOLOGY

IACTA Pharmaceuticals, Inc. | December 16, 2021

IACTA Pharmaceuticals, Inc. an innovation leader in ophthalmic therapeutics, and TALLC Corporation Inc. a pioneering ophthalmology company focused on the growing unmet needs of patients with corneal and retinal conditions, announced that they are entering into a strategic collaboration and licensing agreement. The agreement grants IACTA the use of TALLC’s proprietary SmartCelle™ micellar technology, a novel platform for pan-ocular drug delivery, for future clinical development. IACTA...

Read More
news image

Business Insights

AKORN ANNOUNCES FDA-APPROVED GENERIC CETRORELIX ACETATE FOR INJECTION 0.25 MG

Akorn Pharmaceuticals | August 17, 2022

Akorn Operating Company LLC, a specialty pharmaceutical company, announces that it received FDA approval for a generic version of Cetrorelix Acetate for Injection, 0.25 mg. This is the first approved AP-Rated bioequivalent version of Merck Serono's Cetrotide®.1 "We are pleased to announce the first approved AP-rated generic option for women receiving fertility treatments. As an increasing number of infants are being conceived via the use of ART, ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us